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Background: We sought to characterise a refined rat model of respiratory infection with P. aeruginosa over an acute time course and test the
antibiotic ciprofloxacin.
Methods: Agar beads were prepared±SPAN®80. Rats were inoculated with sterile agar beads or those containing 105 colony forming units (cfu)
P. aeruginosa via intra-tracheal dosing. Bacterial load and inflammatory parameters were measured.
Results: Differing concentrations of SPAN® 80 modified median agar bead diameter and reduced particle size distribution. Beads prepared with
0.01% v/v SPAN®80 were evaluated in vivo. A stable lung infection up to 7 days post infection was achieved and induced BALF neutrophilia 2
and 5 days post infection. Ciprofloxacin (50 mg/kg) significantly attenuated infection without affecting the inflammatory parameters measured.
Conclusion: SPAN® 80 can control the particle size and lung distribution of agar beads and P. aeruginosa-embedded beads prepared with 0.01%v/v
SPAN®80 can induce infection and inflammation over 7 days.
© 2011 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Pseudomonas aeruginosa; Agar beads; Ciprofloxacin1. Introduction
Pseudomonas aeruginosa (P. aeruginosa) is the major
colonising pathogen in cystic fibrosis (CF). Morbidity and
mortality in CF is primarily caused by an excessive inflamma-
tory response and subsequent progressive lung damage
associated with the chronic bacterial infection of the airways
[1]. The inflammatory response associated with chronic
infection is dominated by a neutrophilic infiltrate, where the
excessive release of oxidants and proteases play a central role in
tissue damage [2]. Increased levels of pro-inflammatory⁎ Corresponding author. Tel.: +44 1403 323620; fax: +44 140 3323307.
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doi:10.1016/j.jcf.2010.12.007cytokines and reduced levels of anti-inflammatory cytokines
are also present [3]. The rat model of chronic respiratory
infection with P. aeruginosawas first described by Cash et al. in
1979 [4] and similar models in which mice are infected with
P. aeruginosa embedded in agar beads are extensively used [5–
8]. While these models mimic aspects of CF, a key challenge for
these models, where an infectious agent is embedded in beads,
has been the ability to routinely produce beads of a standard size
and particle distribution, as marked heterogeneity in size and
distribution is typically observed.
The primary aim of this study was thus to develop a method
to control the particle size and distribution of agar beads
embedded with bacteria using the non-ionic surfactant SPAN®
80. Using standardized beads we then sought to characterise an
acute time course of the infection and inflammatory changes
together with evaluating the effect of the clinically used
antibiotic ciprofloxacin.d by Elsevier B.V. All rights reserved.
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2.1. Preparation of agar beads embedded with P. aeruginosa
Using a modified version of the method described by Cash
et al. [4], an overnight culture of P. aeruginosa PAO1V strain
(courtesy of Mike Vasil, University of Colorado) was prepared
in tryptic soy agar broth (TSB) (Beckton & Dickenson, UK).
PAO1V, a partially mucoid strain, is a derivation of the PAO1
strain which itself is widely used in this model. The bacteria
were embedded into agar beads by mixing the overnight culture
with molten 2% w/v agar noble (Beckton & Dickenson, UK)
which was then spun into warmed mineral oil (Sigma Aldrich,
UK)±0.1% v/v or 0.01% v/v the non-ionic surfactant SPAN®
80 (Sorbitan monooleate, Sigma Aldrich, UK). The mineral oil
was cooled, the beads centrifuged at 10,000 g for 20 min and
then washed with phosphate buffered saline (PBS) pH 7.2
(Invitrogen, UK). A cfu determination was performed on the
bead slurry by growing P. aeruginosa colonies on tryptic soy
agar (TSA) plates with 5% sheep blood (Beckton & Dickenson,
UK). The slurry was diluted with PBS pH 7.2 to obtain the
desired cfus. Sterile beads were prepared using PBS. Bead
preparations were sized using a Mastersizer 2000™ (Scirocco
2000, Malver Instruments).
2.2. Inoculation of male Sprague–Dawley rats with P. aeruginosa
Animal work was performed under the UK Animal
(Scientific Procedures) Act, 1986. On day 0, male Sprague–
Dawley rats (250–320 g, n=16/group, Charles River, UK) were
inoculated with 105 cfu of P. aeruginosa embedded into agar
beads into their left lung via intra-tracheal dosing under
isoflurane anaesthesia (Virbac Ltd, UK). A sham group were
inoculated with sterile agar beads. Body weight was measured
daily, and animals were observed for signs of pain and distress.
The model was characterised over time by euthanizing sham
and infected animals 2, 5 or 7 days post inoculation.
Additionally, the antibiotic ciprofloxacin was tested to
determine if the lung infection could be attenuated. On day 1,
animals were subcutaneously dosed with either 50 mg/kg
ciprofloxacin (Hospira Inc, USA) or vehicle (saline). Sham
animals were treated with vehicle. A further dose was
administered in the evening of day 1. Animals were then
euthanized on the morning of day 2. The dosing schedule was
selected based on previous experience with this antibiotic and
its efficacy in rodent infection models.
2.3. Lung harvest formicrobiological and histological assessment
At the appropriate time point post infection, 8 animals from
each group were euthanized by administering an overdose of
sodium pentobarbitone (Merial, UK). cfus were determined for
homogenised lungs by serially plating onto TSA blood agar
plates. Additionally, samples of kidney, spleen and blood were
taken to monitor for the presence of systemic infection. The
remaining 8 animals in each group were euthanized, the trachea
cannulated and a bronchoalveloar lavage (BAL) performedusing PBS pH 7.4 (Invitrogen, UK), to determine total and
differential BAL cell counts. The left lungs were inflated with
10% (v/v) buffered formalin (VWR, UK) and immersion fixed
for 24–48 h. The fixed lung was sliced tangentially into 6 slices
and the 4 central slices processed as one block. After
processing, de-waxed sections were treated with 1% (v/v)
aqueous acetic acid for 2 min and subsequently with 1% (w/v)
aqueous alcian blue (Fluka, Sigma Aldrich, UK) for 30 min
before the application of a routine haematoxylin and eosin stain
(AB-H&E) to permit histological assessment. Additional
sections were cut and stained for CD3 (monoclonal rabbit
CD3, Sigma Aldrich, UK); de-waxed sections were treated with
primary CD3 antibody for 60 min.
2.4. Total and differential cell counts from bronchoalveolar
lavage fluid (BALF)
The collected BALF was mixed vigorously by inverting the
tube and an aliquot was removed for differential cell counting:
cytospin slides were prepared by loading sample into the
corresponding cytospin funnel and centrifuged at 700 rpm for
5 min with a slow acceleration (Shandon Cytospin 4, Thermo-
scientific). The slides were then stained with Wright's stain.
Under a light microscope the number of macrophages,
neutrophils, lymphocytes and eosinophils in a total of 200
cells were determined at 40× magnification. The remaining
BALF was centrifuged at 320 g for 10 min at 4 °C. Aliquots
were removed and stored at −80 °C. The cell pellet was re-
suspended in 1 ml of methyl violet fixative (0.01% methyl
violet, 1.5% acetic acid Sigma Aldrich, UK) and stored at 4 °C.
A total cell count was performed using a multi-chamber
haemocytometer. Total cell count was subsequently used to
extrapolate back the number of macrophages, neutrophils,
lymphocytes and eosinophils in the sample. IL-1β, CINC-3 and
IFNγ were measured in BALF supernatant using ELISA kits
(R&D Systems), according to manufacturer's instructions.
2.5. Histopathological scoring
A scoring system was developed to assess the histopatho-
logical changes in the lung tissue on four criteria: broncho-
pneumonia, interstitial inflammation, epithelial changes and
goblet cell hyperplasia. The lung sections were then blindly
scored on a scale of 0–5, with 0 being no change and 5 being the
greatest change (i.e. “severe”, meaningN80% of lung paren-
chyma being affected), for each criterion. CD3+ staining of
sections was analysed using Aperio ImageScope v 9.1.19.1569.
2.6. Statistical analysis
All data are presented as the mean±standard error of mean
(SEM), except for bead size which was expressed as median±
SEM. All data were analyzed using GraphPad Prism 4.0
(GraphPad software, San Diego, CA). Comparisons were made
using Kruskall Wallis one-way analysis of variance followed by
a Dunn's multiple comparison test. A value of Pb0.05 was
taken to be statistically significant.
168 E.J. Growcott et al. / Journal of Cystic Fibrosis 10 (2011) 166–1743. Results
3.1. The use of SPAN® 80 to standardise agar bead particle
size distribution
Initial experiments ascertained the effect of 0.01% v/v and
0.1% v/v SPAN® 80. Without SPAN® 80 the median particle
size for the beads formed was 539±57 μm (distribution at 50%,
d0.5) (Fig. 1). In addition the bead population was heteroge-Fig. 1. The effect of SPAN®80 on agar bead particle size (μm) distribution as measure
80, B, 0.01% SPAN 80 or C 0.1% SPAN® 80. Images are representative of n=3 separ
distribution at 90%. Data are presented as mean±SEM of n=3 separate preparationneous. 0.01% v/v and 0.1% v/v SPAN® 80 reduced the median
particle size of the beads (Fig. 1) as well as producing more
homogeneous bead populations by reducing the particle size
distribution (Fig. 1). In order to ascertain the effect of bead size
on lung distribution, a comparison was made between the
largest (0% SPAN 80®) and the smallest (0.1% v/v SPAN 80®)
bead populations. The beads were administered intra-tracheally
and two days post infection beads prepared with 0% SPAN 80®
were found to have a wide distribution in the lungs, reflectingd using a Mastersizer 2000. Agar beads were prepared with either A, no SPAN®
ate preparation. d0.1— distribution at 10%, d0.5— distribution at 50%, d0.9—
s.
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in the alveolar spaces while large beads also were lodged in the
larger airways (Fig. 2A). In contrast, beads prepared with 0.1%
SPAN 80® were found primarily in the alveolar spaces
(Fig. 2B). The lung bacterial load from the 0% and 0.1%
SPAN 80® beads was found to be similar resulting in 5.9±0.9,
0.1% SPAN 80 6.1±0.3 log cfu respectively. When compared,
the two bead populations elicited similar total cell and
neutrophil numbers present in the BALF on both infected and
sham animals (Fig. 2C–D) indicating that bead size does not
appear to affect lung bacterial load or P. aeruginosa-induced
inflammation.
Beads produced with 0.01% v/v SPAN® 80 were selected for
further characterisation in vivo. Although these beads had a
greater particle size distribution than those produced with 0.1%
v/v SPAN® 80 it was felt that the median bead size would
enable the beads to lodge in the small airways and thus be more
reflective of CF.
3.2. Time course of infection and inflammation using agar
beads prepared with 0.01% v/v SPAN®80
The lung bacterial load was found to be 5.97±0.17, 6.19±
0.15, 5.95±0.15 log cfu 2, 5 and 7 days post inoculationFig. 2. Representative images from P. aeruginosa treated lung sections inoculat
(B) 2 days post infection and stained with alcian blue and haematoxylin and e
neutrophils present in BAL fluid 2 days post infection. Data are expressed as th
Pb0.05 versus 0.1% v/v SPAN 80® sham.indicating a stable infection. No evidence of systemic infection
was observed (data not shown) and no bacteria were present in
the sham groups either in the lungs or systemically.
P. aeruginosa induced a 3–4 fold increase in the total
number of cells present in the BAL fluid compared to sham
(7.23±1.26×106 cells versus 1.95±0.13×106 cells respec-
tively, n=7–8) 2 days post infection and an approximate 2-fold
increase in BAL fluid cells at day 5 (2.25±0.39×106 cells
compared to 1.20±0.13×106 cells respectively, Pb0.05,
n=7–8) (Fig. 3A). The increased BALF cells reflected an
increase in neutrophil number (5.63±1.20×106 compared to
sham 0.23±0.05×106 cells, Pb0.05 at day 2 and 1.00±
0.38×106 compared to sham 0.03±0.01×106 cells, Pb0.01 at
day 5) (Fig. 3B). No significant changes in macrophages,
eosinophils or lymphocytes were observed (data not shown).
No significant changes in BALF cell numbers were observed
at day 7.
The histopathological findings are illustrated in Fig. 4.
Lesions were primarily observed in the lower half of the left
lung. Two days post infection, P. aeruginosa-treated animals
had an increase in the inflammatory infiltrate in the airway
lumen and alveolar spaces (bronchopneumonia). This was
primarily neutrophilic in nature compared to the predominance
of alveolar macrophages observed in sham animals. Thised with agar beads prepared with 0% SPAN 80® (A) and 0.1% SPAN 80®
osin (arrow pointing to agar beads). The number of C, total cells and D,
e mean±SEM of 5–6 animals. **, Pb0.01 versus 0% SPAN 80® sham; #,
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Fig. 3. The number of A, total cells and B, neutrophils present in BAL fluid 2,
5 and 7 days post infection. Data are expressed as the mean±SEM of 7–
8 animals. *, Pb0.05 versus sham; **, Pb0.01 versus sham.
Fig. 4. Representative images from sham and infected lung sections stained with alcia
2; C, sham day 5; D, 105 cfu P.aeruginosa day 5; E, sham day 7 and F, 105 P. aeru
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when it was replaced by macrophages and fibroblasts (chronic
inflammatory changes) (Fig. 5A). In both sham and infected
animals, at all three time points, peri-vascular and peri-
bronchiolar eosinophils were observed, but this was more
marked in the infected animals, where interstitial oedema was
also present (Fig. 5B). Infected rats had marked changes in the
epithelium at days 2, 5 and 7 post inoculation, characterised by
hyperplasia and hypertrophy as well as disruption of the
basement membrane at earlier time points (Fig. 5C). Changes in
mucus were also observed as measured by alcian blue staining.
Alcian blue staining was increased in the infected group at day 2
and was more marked at days 5 and 7 (Fig. 5D). Indeed there
appeared to be evidence of mucus plugging in the airway lumen
at day 5. A significant increase in the number of CD3+ stained
cells as a ratio of the total staining was observed at day 5
(Pb0.05, n=8) and day 7 (Pb0.001, n=8) in the lung tissue of
infected animals compared to corresponding sham rats
suggesting an increase in lymphocytic infiltrate (Fig. 5E).
CINC-3 levels were below the detection limit in the BAL
supernatant of sham animals however, CINC-3 was signifi-
cantly increased in the infected animals at day 2 (104.8±
37.0 pg/ml, Pb0.01, n=7–8) and day 5 (168.0±68.8 pg/ml,
Pb0.01, n=7–8) post infection. IL-1β was also significantly
elevated in the infected animals compared to the sham groups
(also below the limit of detection) at day 2 (263.7±50.7 pg/ml,
Pb0.001, n=7–8), day 5 (140.7±18.8 pg/ml, Pb0.01, n=7–8)
and day 7 post infection (119.3±17.0 pg/ml, Pb0.05, n=7–8).
IFN-γ was only significantly elevated in the infected animals atn blue and haematoxylin and eosin. A, sham day 2; B, 105 cfu P. aeruginosa day
ginosa cfu day 7. Arrow pointing to agar bead.
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Fig. 5. Histological scoring for sham (open squares) and infected animals (closed squares) 2, 5 and 7 days post infection. Sections were scored on 4 criteria:
A, bronchopneumonia; B, interstitial changes; C, epithelial changes and D, changes in mucus staining. Data are presented as the individual score for each animal
with the mean of the group. E, CD3 specific staining for lymphocytes in sham (open squares) and infected (closed squares) 2, 5 and 7 days post infection.
Sections were analysed using Aperio ImageScope v 9.1.19.1569. Data are presented as the mean±SEM of CD3+ staining as a ratio of total staining. *, Pb0.05
versus sham; ***, Pb0.001 versus sham.
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13.1±8.5 pg/ml respectively, Pb0.05, n=7–8 animals).
3.3. The effect of ciprofloxacin on infection and inflammation
The effect of the antibiotic ciprofloxacin was tested using the
refined bead preparation as part of the model validation. Insham animals, lung infection was absent compared to the
infected vehicle-treated group which had a significant lung
infection of 5.57±0.16 log cfu. Treatment with 50 mg/kg
ciprofloxacin significantly attenuated infection to 1.65±0.15
log cfu, Pb0.01, n=7–8).
The effect of ciprofloxacin on P. aeruginosa-induced
inflammation was also investigated. BALF from vehicle-treated
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Fig. 6. Histological scoring for vehicle-treated sham (open squares), vehicle-treated infected (closed squares) or 50 mg/kg ciprofloxacin-treated infected animals (grey
squares). Sections were scored on 4 criteria: A, bronchopneumonia; B, interstitial changes; C, epithelial changes and D, changes in mucus staining. Data are presented
as the individual score for each animal with the mean of the group.
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present versus sham treated rats (5.03±0.92×106 and 1.59±
0.18×106 cells respectively, Pb0.001, n=8–9), reflected by a
significant increase in neutrophils (3.53±0.76×106 and 0.21±
0.05×106 cells, Pb0.001, n=8–9). This was not significantly
altered by ciprofloxacin (2.67±0.70×106 neutrophils). Cipro-
floxacin had no effect on the histopathological findings (Fig. 6).
BALF levels of CINC-3 were significantly elevated in
infected vehicle-treated animals (36.32±9.54 pg/ml, Pb0.05)
compared to sham animals (undetectable). There were no
significant changes in the levels of IL-1β in infected vehicle-
treated animals compared to sham animals (105.60 ±
30.50 pg/ml versus 21.54±14.37 pg/ml). IL-1β and CINC-3
levels were not affected by ciprofloxacin treatment (72.19±
27.60 pg/ml and 26.56±10.51 pg/ml respectively).
4. Discussion
The addition of the non-ionic surfactant SPAN® 80 during
the preparation of agar beads embedded with bacteria controlledthe median agar bead diameter (with some evidence of
concentration dependence) and particle size distribution,
allowing the reproducible production of a more homogeneous
bead population of a defined size.
The ability to control agar bead particle size and
distribution could have a number of significant advantages,
for example, in addition to rat lung infection models, this novel
methodology could impact on mouse lung infection models,
where the production of small beads is critical due to the
relatively small size of mouse airways. In particular, infection
of cystic fibrosis transmembrane conductance regulator
protein knock out (cftr−/−) mice (or mice which model specific
mutations in cftr) with P. aeruginosa embedded in agar beads
is a fairly widely used model system [5–9]. Standardisation of
agar bead size is expected to improve animal welfare, as large
beads have the potential to block the airways, leading to
respiratory distress.
Using beads standardized with 0.01% v/v SPAN 80®,
P. aeruginosa colonies were recoverable up to 7 days post
infection, whilst no systemic infection was observed. The log
173E.J. Growcott et al. / Journal of Cystic Fibrosis 10 (2011) 166–174cfu values achieved at days 2 and 7 post infection were
comparable to similar time points reported in the literature
using PAO1 [10,11]. A clear pro-inflammatory effect of
P. aeruginosa infection as measured by a significant increase
in neutrophils and cytokines in the BAL fluid and lung tissue
of infected versus sham animals was observed. The increase in
neutrophils observed in BAL fluid 2 days post infection is
consistent with data published by Cantin et al. [10] 3 days post
infection. However, unlike Cantin et al., where the neutrophils
present in BAL fluid remained constant up to 9 days post
infection, in these studies a drop in the neutrophil number in
BAL fluid was observed at day 5, and by day 7 no clear
difference between sham or infected animals was seen. The
neutrophil cell counts presented here, are however consistent
with the observations of Boyer et al. [12] over a similar time
scale (2–8 days) and also consistent with those reported by
Amano et al. [13]. Whilst the mechanisms underlying
neutrophil recruitment are unclear, a reduction in the number
of neutrophils observed in BAL fluid is associated with lower
levels of the neutrophil chemoattractant CINC-3 as well as IL-
1β in the BAL fluid. The elevation of IFN-γ in the BAL fluid
at day 7 could suggest the initiation of a T cell response and
perhaps therefore a shift from the innate to the adaptive
immune response. This is supported by the histological
analysis of tissue sections for CD3+ staining where a
significant increase in CD3+ staining was observed at days 5
and 7. Amano et al. [13] also observed an increased number of
lymphocytes albeit in BAL fluid rather than lung tissue 7 days
post infection. Therefore, it is suggested that the nature of the
inflammation in this model is changing over time, so that by
day 7 a more chronic inflammation is present, as evidenced by
a significant increase in the number of CD3+ cells present in
the tissue.
The histopathology observed acutely in this model resembles
that seen by Cash et al. [4] and has similar characteristics to the
pathology observed in CF (neutrophilic infiltrate and remodel-
ling/thickening of the airway epithelium, mucus plugging). In
agreement with the findings of Cash et al. we have observed
increases in mucus using an alcian blue stain. The lung
histopathology is also reflective of the BALF data in that after
day 2, the acute inflammatory infiltrate (i.e. the neutrophils)
begins to decline. At later time points, macrophage and
fibroblastic components are (chronic inflammatory compo-
nents) present in the tissue, as well as structural changes such as
epithelial hyperplasia.
A number of compounds used clinically to treat CF for
example tobramycin (anti-microbial) [14] and ibuprofen (anti-
inflammatory) [15] have shown efficacy in this model system
as has ciprofloxacin, a fluoroquinolone antibiotic used
clinically as an early eradication therapy for P. aeruginosa
in CF patients [16–18]. In a study to investigate resistance
selection, rats inoculated with 106 cfu PAO1 and then treated
with ciprofloxacin (12.5 mg/kg i.p.) every 5 h showed a 2 log
reduction in cfu 34 h post infection [18]. We observed a more
dramatic decrease in lung bacterial load (4 log reduction
2 days post infection) using a higher dose of ciprofloxacin
administered s.c. BID.We also sought to investigate the effect of ciprofloxacin on
inflammatory parameters as there is evidence that some
fluroquinolones containing a cyclopropyl moiety such as
ciprofloxacin can have an immunomodulatory effect (reviewed
in Dalhoff and Shalit [19]). For example, in a model of acute
lung injury with lipopolysaccharide in mice, prophylactic
ciprofloxacin (200 mg/kg) treatment reduced the levels of
cytokines (including IL-1β) in BALF 3 and 6 h post challenge
[20]. Sub-inhibitory anti-microbial treatment with ciprofloxacin
also reduced P. aeruginosa tissue injury in the rat model of
respiratory infection in which bacteria were embedded in agar
beads [21]. However, no immunomodulatory effects of
ciprofloxacin were observed in our study. There are a number
of potential reasons for our different findings for example, route
of compound administration, inflammatory stimulus used (LPS
or live bacteria), bacterial dose used and time points evaluated.
Future studies will also include investigating additional
antibiotics and dosing strategies to investigate the relationship
between infection and inflammation.
In conclusion, the addition of the non-ionic surfactant
SPAN® 80 can control the particle size and has the potential to
enable a controlled distribution of agar beads embedded with
bacteria. This represents advancement for this model in that we
now have the capability to generate a more homogenous agar
bead population of a specific size distribution. Furthermore,
using the anti-microbial ciprofloxacin, we have shown a
dissociation between infection and inflammation at the 2 day
time point in this model i.e. ciprofloxacin attenuated infection
whist having no effect on lung inflammatory parameters
measured here. In theory this novel method using defined
concentrations of SPAN® 80 could enable specific targeting of
the inoculums to different regions of the airways within the
lung, and facilitate the assessment of novel anti-infectious and
anti-inflammatory agents in this refined model system.
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